84771-33-5Relevant articles and documents
Selective Inhibition of the Immunoproteasome by Structure-Based Targeting of a Non-catalytic Cysteine
Dubiella, Christian,Baur, Regina,Cui, Haissi,Huber, Eva M.,Groll, Michael
, p. 15888 - 15891 (2015)
Clinically applied proteasome inhibitors induce cell death by concomitant blockage of constitutive and immunoproteasomes. In contrast, selective immunoproteasome inhibition is less cytotoxic and has the potential to modulate chronic inflammation and autoi
Intermolecular (4+3) cycloadditions of aziridinyl enolsilanes
Lam, Sze Kui,Lam, Sarah,Wong, Wing-Tak,Chiu, Pauline
supporting information, p. 1738 - 1741 (2014/02/14)
Upon activation by strong Bronsted acids, aziridinyl enolsilanes undergo (4+3) cycloadditions with dienes to afford aminoalkylated cycloheptenones as products. The use of a highly polar medium such as nitroalkane facilitates high cycloaddition yields of up to 99%. Optically pure aziridinyl enolsilanes react to yield (4+3) cycloadducts with up to 99% ee.
On The Synthesis of (2S)-Aziridine-2-Carboxylic Acid Containing Peptides
Korn, Andreas,Rudolph-Boehner, Sabine,Moroder, Luis
, p. 1717 - 1730 (2007/10/02)
Optimized conditions are described for the synthesis of 1-trityl-2-aziridine-carboxylic acid 3 (Trt-Azy-OH) and benzyl (2S)-aziridine-2-carboxylate 6 (H-Azy-OBzl) as useful derivatives for the synthesis of N- and C-terminal aziridine-containing peptides.Thereby, the use of the pentafluorophenyl ester of Trt-Azy-OH was found to be the method of choice in acylating steps, whereas acylation of H-Azy-OBzl several classical methods of peptide synthesis can be succesfully used.The fully protected aziridine-2-carboxylic acid peptides are accessible in satisfactory yields as analytically defined products, but partial or total deprotection of these compounds again by standard procedures of peptide synthesis is surprisingly difficult in terms of satisfactory yields, whereby sequence-dependent unstability both in the reaction and purification steps as well as on storage was found to strongly limit the accessibility of these aziridine-containing peptides as promising active-site inactivators of cysteine-proteinases.